The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

In short, everything that makes Clawdbot unique and helpful also makes it potentially risky. Generally, AI processes that ...

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Japan’s Eisai and US biotech Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...

New Delhi, January 22 (IANS): The Supreme Court on Thursday reserved its order on a public interest litigation (PIL) seeking ...

As per the petition, hanging should no longer be used as a mode of execution and alternatives such as lethal injection should be considered ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...